Goal Management Training, Executive Functions and HIV
Efficacy Potential of Goal Management Training to Improve Cognitive Function in Older People Living With HIV
Goal Management Training (GMT) is a cognitive rehabilitation program targeting executive dysfunction (problems with attention, reasoning, problem solving, planning, etc), which is a central problem in HIV-associated neurocognitive disorder. It teaches self-management principles, stress management and mindfulness, and trains participants in the use of several strategies to reduce cognitive load in everyday tasks, and methods to cue attention to maintain focus on specific tasks. GMT is a manualized protocol with set content conveyed through a combination of slides and a workbook. Two-hour small group sessions are led, in person, by a trained therapist once a week, for nine weeks. The small group sessions allow participants to learn from each other, enhancing engagement. GMT has been shown to improve cognitive function in a variety of neurological conditions, as well as in healthy older people with cognitive concerns. These improvements have been shown to last at least 6 months in some studies and are accompanied by changes in the brain networks underlying executive function. GMT is thus a well-validated, high yield intervention with which to test the potential of cognitive rehabilitation in older HIV+ people with cognitive concerns.
The researchers hypothesize that GMT will lead to improved cognitive function as assessed by better performance on cognitive tests and reduced self-reported cognitive difficulties in people with stable HIV infection who report cognitive difficulties at baseline.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Rehabilitation is a well-established approach to maintain function in the face of chronic disease, and holds promise for addressing the health challenges faced by older people with HIV. A Canadian-led knowledge synthesis review published in 2014 identified cognitive rehabilitation as a promising approach in HIV, but highlighted the absence of high quality, HIV-specific evidence in this area. A recent focused review also highlights the dearth of evidence on this topic. Very few studies have been published, and to date all have been restricted to computerized training programs only. While there is limited evidence for computerized cognitive rehabilitation in any context, there is better evidence for more conventional, in-person rehabilitation approaches, at least in other neurological disorders. Although computerized training is appealing because it is more feasible to deliver on a wide scale than conventional cognitive rehabilitation, The researchers propose that the first step should be to establish an evidence base regarding the efficacy of any form of cognitive rehabilitation in HIV. Evidence of efficacy of a 'high dose' established rehabilitation method could be followed by work to define the key elements, and to study how those elements could be delivered most cost-effectively, but there is no point in pursuing these secondary steps if the most well-established cognitive rehabilitation approaches do not show efficacy. Thus, the researchers propose to test conventional rehabilitation as a crucial first step is a research program focused on evidence-based interventions for improving brain health in HIV.
There is no gold standard conventional cognitive rehabilitation program, but most existing approaches combine face-to-face therapy with at home practice over a period of at least several weeks. In the absence of a gold standard, the researchers have selected one such program: Goal Management Training (GMT). This program targets executive dysfunction, which is a central problem in HIV-associated neurocognitive disorder. GMT is grounded in a neurobiological framework and was developed based on nearly two decades of research on practical approaches to minimizing the impact of executive dysfunction, aiming to help people with brain injury manage real life tasks. The program teaches self-management principles, stress management and mindfulness, and trains participants in the use of several explicit strategies to reduce cognitive load in everyday tasks, and methods to cue attention to maintain focus on specific tasks. GMT is a manualized protocol with set content conveyed through a combination of slides and a workbook. Two-hour small group sessions are led, in person, by a trained therapist once a week, for seven weeks. The small group sessions allow participants to learn from each other, enhancing engagement. GMT has been shown to improve cognitive function in a variety of neurological conditions, as well as in healthy older people with cognitive concerns. Evidence from randomized trials shows that this intervention leads to (i) significant improvements in performance on cognitive tests, including naturalistic tests of real life tasks, (ii) reduced self-reported cognitive difficulties, and (iii) significant improvements in everyday function compared to either a wait-list condition or a general brain health education control. Positive effects have been found in older people with cognitive difficulties, and neurological populations with mild cognitive impairment including mild traumatic brain injury, stroke and spina bifida. These improvements have been shown to last at least 6 months in some studies and are accompanied by changes in the brain networks underlying executive function. GMT is thus a well-validated, high yield intervention with which to test the potential of cognitive rehabilitation in older HIV+ people with cognitive concerns.
The pilot project is nested within an ongoing observational cohort study that aims to understand and address the heterogeneous, multi-factorial nature of compromised brain health in people living with HIV. Study participants will be randomly selected from those participating in the ongoing, longitudinal Positive Brain Health Now (+BHN) study at 2 sites in Montreal (The Montreal Chest Institute and L'Actuel Medical Clinic). This CIHR Team Grant-supported observational, prospective cohort study has enrolled 840 consecutive patients attending 5 HIV clinics across Canada, who are followed every 9 months for 27 months.
Procedure Participants will be recruited either at the time of their routine +BHN study visit, or by phone or by email. Informed consent will occur with the therapist during the first GMT group session during which they will also complete a questionnaire regarding any cognitive concerns they may have (Communicating Cognitive Concerns-C3Q). At the end of the last GMT session, they will be asked to complete the C3Q again. Then, within 4 weeks of completing the GMT program, they will be asked to repeat the B-CAM, coincident with the +BHN study visit if timing permits.
Intervention The standard GMT program lasts 9 weeks and involves 9 weekly 2-hour small group sessions led by a trained therapist. It follows a manualized program that teaches participants a series of techniques to build attention and executive function, and shows them how to implement these techniques in their everyday life. The small group sessions allow individualization of the training to show how it can be applied to meet the particular challenges reported by participants, and explicitly encourage participants to share their challenges and successes with others in the group to promote learning and engagement with the program. The sessions are reinforced with homework, in which participants practice what they have learned. Sessions will be audiotaped for later review by the trainer and/or study investigators to ensure adherence to the intervention manual. The material, including homework, is provided in a workbook that participants use throughout the training, and keep for later reference.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Center
-
Montreal, Quebec, Canada, H2L 4P9
- Clinique Médicale l'Actuel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV infection for at least 1 year
- Able to communicate in French or English
- Capable of providing informed consent
- Over 45 years old
- Subjective cognitive complaints
- Performance on objective computerized cognitive tests that falss at or below 50th percentile of performance in the cohort (main study) as a whole)
Exclusion Criteria:
- Presence of dementia
- Life expectancy of 3 years or less
- Other neurological disorder including opportunistic CNS infection, psychotic disorder
- Current substance dependence or abuse
- Hepatitis C requiring interferon therapy during the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: GMT Intervention
Over the course of 9 weeks, there are 2h-group sessions with a therapist.
|
|
|
NO_INTERVENTION: Control
Group not getting the intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance measure (B-CAM)
Time Frame: Up to 9 months before the intervention and up to 2 months after the intervention
|
We will be looking at changes on the B-CAM (brief cognitive ability measure) pre- and post-intervention
|
Up to 9 months before the intervention and up to 2 months after the intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tower of London (cognitive outcome measure)
Time Frame: Up to 9 months before the intervention and up to 2 months after the intervention
|
Assesses planning and mental flexibility
|
Up to 9 months before the intervention and up to 2 months after the intervention
|
|
Communicating Cognitive Concerns (C3Q)
Time Frame: On the first day of the intervention and 9 weeks after the beginning of the intervention
|
Evaluates cognitive concerns participants may have
|
On the first day of the intervention and 9 weeks after the beginning of the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lesley Fellows, MD/PhD, McGill University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- MUHC-16-031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
NCT07218211RecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis Use
-
NCT07618507Completed
-
NCT05384145RecruitingHIV | HIV Testing | HIV Linkage to Care | HIV Treatment
-
NCT07509827RecruitingHIV Prevention | PrEP Adherence | HIV Related Stigma
-
NCT07231640RecruitingPrEP | HIV | HIV Prevention | PrEP Uptake
-
NCT07194902RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum Women
-
NCT02570334UnknownHIV | HIV-uninfected Children | Children Exposed to HIV
-
NCT01494961CompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV Incidence
-
NCT04144335WithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and Infections
-
NCT07226492RecruitingPregnancy | HIV | Post-partum | HIV Antiretroviral Therapy (ART) Adherence
Clinical Trials on GMT intervention
-
NCT06604000RecruitingAcquired Brain Injury | Executive Function Disorder
-
NCT05494424Active, not recruiting
-
NCT03048695CompletedNeurocognitive Disorders | Schizophrenia
-
NCT06354361CompletedPost-Traumatic Stress Disorder
-
NCT04457271WithdrawnPTSD | Cognitive Impairment | Cognitive Dysfunction | Cognitive Deficit | Post-traumatic Stress Disorder
-
NCT01302314CompletedExecutive Dysfunction | Spina Bifida | Cognitive Deficits
-
NCT04882215TerminatedAcquired Brain Injury
-
NCT04503798UnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive Impairment
-
NCT04541056Active, not recruitingChildhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia | Childhood Non-Hodgkin Lymphoma
-
NCT01714531CompletedTraumatic Brain Injury